A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.
Yasemin CagSacit IctenBurcu Isik-GorenNaciye Betul BaysalBegum BektasEce SelviPinar ErgenOzlem AydinAyse Canan UcisikFatma Yilmaz-KaradagHulya CaskurluTulin Akarsu-AyazogluHasan KocogluSinan UzmanMuge Nural-PamukcuFerhat ArslanGurhan BasMahmut Tayyar KalciogluHaluk VahabogluPublished in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2020)
This manuscript aims to present a treatment algorithm we applied to manage COVID-19 patients admitted to our hospital. During the study period, 2043 patients with suspected COVID-19 were admitted to the emergency department. Molecular tests indicated that 475 of these patients tested positive for COVID-19. We administered hydroxychloroquine plus doxycycline to mild cases (isolated at home) for 3 days and lopinavir plus doxycycline to moderate and severe cases (hospitalized) for 5 days. The overall case fatality rate was 4.2% (20/475).